Base Year
Historical Year
Forecast Year
The rising prevalence of asthma drives the value of the bronchial spasms treatment market size. The number of asthma cases was nearly 306.09 million in 2023. The prevalence of the disease is likely to grow at a rate of 4.0% in the forecast period of 2024-2032. With this growth rate, the number of cases expected in 2032 is approximately 435.67 million.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Bronchial spasms are among the most common pulmonary disorders. In bronchial spams, the muscles around the bronchial tubes contract or inflame and obstruct the airway flow. This leads to irregular or short breathing and, in extreme situations, can lead to death.
The most common symptoms of bronchial spasms include wheezing, pain in the chest, difficulty in breathing and coughing. The contraction and inflammation of bronchial muscles are due to the associated pulmonary disorders like emphysema, asthma, bronchitis, or chronic obstructive pulmonary disease (COPD).
Bronchial spasms are likely to affect children, older adults, and people with weakened immune systems. People suffering from other allergies like food allergies or eczema are also expected to develop bronchial spasms.
Early diagnosis of bronchial spasms is important for proper therapeutic intervention. The diagnosis is done using tests like CT scans, chest X-rays, mucus testing or other imaging tests. Spirometry is an important diagnostic test used to measure the amount of air inhaled and exhaled through the lungs.
Treatment interventions for bronchial spasms depend on the pathophysiology and the severity of the disease. The effective treatment strategies are administering inhaled steroids, use of , and changes in lifestyle patterns.
According to the bronchial spasms treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Diagnosis Type
Market Breakup by Treatment Type
Bronchial Spasms Treatment Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The bronchial spasms treatment market is driven by the increasing prevalence and incidence of respiratory disorders like emphysema, asthma, chronic bronchitis, and chronic obstructive pulmonary disorder. In 2021, around 283 million people were diagnosed with asthma, which is why there is more demand for more air inhalers, facilitating market growth.
Technological advancements are one of the primary drivers attributing to the development of the market. Healthcare products are getting better and better with the rapidly evolving innovative technologies. For example, with the invention of smart inhalers, patients can poise their dosage and take it according to their suitability.
The additional factors supplementing the market growth include rising adoption of IoT devices, increasing geriatric population, and increased investments by the key players.
Short-acting bronchodilators account for the largest share of the global market. This can be attributed to its immediate therapeutic effect in treating acute or chronic bronchial spasms.
North America will hold a significant share of the bronchial spasms treatment market. This is due to the technological advancements, rising geriatric population, increasing awareness and more research and developmental activities.
There are several treatment strategies for the management of bronchial spasms. Through diagnostic studies, the healthcare provider provides the best possible treatment. The treatment of bronchospasms is done with bronchodilators. The bronchodilators are administered through air inhalers, nebulisers, or tablet dosage forms.
The bronchodilator type is prescribed to assess the extremity of the situation. Short-acting bronchodilators are generally defined in case of immediate or rapid effects. This type of medication can open the blocked pathways within minutes. Some examples of these medications are Levalbuterol and Albuterol.
The long-acting bronchodilators take longer time to show their therapeutic effects but effectively reduces the risk of bronchospasms in the near future. Some long-acting bronchodilators are Aclidinium, Arformoterol, Formoterol, Glycopyrrolate, Indacaterol, Olodaterol, Salmeterol, and Tiotropium.
In case of severe or chronic bronchitis, inhaled steroids are incorporated as a therapeutic intervention. The steroids reduce the inflammation around the bronchial muscles. The oral and intravenous routes are the optimal administration routes for steroids.
Tremendous efforts of scientists, researchers, and healthcare professionals will lead to innovative therapies that will lay the foundation for next-generation technologies.
Henceforth, all these novel treatments will help improve healthcare and the global economy. These new treatment strategies will majorly drive the growth of the global bronchial spasms treatment market in the forecast period.
With extensive research and development, novel treatment methods are being discovered, projected to boost the growth of the bronchial spasms treatment market. During the clinical trials, combination therapies proved excellent treatment sources due to their synergistic therapeutic action.
Incorporating two monotherapies, inhaled corticosteroids, and short-acting beta two agonists as a single combined therapy will provide dual therapeutic action. The corticosteroids help reduce inflammation in bronchial airways and potentiate short-acting bronchodilators' therapeutic response.
In 2023, Pantherics Inc., a key player, received funds of USD 255,000 from the National Institutes of Health. This will facilitate the clinical trials for a novel bronchospasms drug that will be used to manage asthma and other pulmonary disorders.
The clinical trials are also done to increase patient awareness and adherence to the prescribed medication schedule. For example, in 2023, Boehringer Ingelheim Pharmaceuticals and HealthPrize conducted a program to educate chronic obstructive pulmonary disorder patients about medication adherence.
Implementing technology in healthcare has already provided enormous benefits to human health. Researchers’ tremendous efforts have anticipated a rapid increase in the approvals for bronchial spasms therapies. Several ongoing clinical trials are emerging as a key driving factor for market growth and development.
The report gives an in-depth analysis of the key players involved in the bronchial spasms treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis Type |
|
| Breakup by Treatment Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Bronchodilators are the medications used for widening the obstructed or blocked bronchial pathways and thus helps in normal breathing.
Increasing prevalence of pulmonary disorders, technological advancements, increased research and developmental activities, and better awareness are the driving factors of the market.
Based on the diagnosis type, the market is segmented into spirometry tests and imaging tests, among others.
Based on the treatment type, the market is categorised into long-acting bronchodilators, short acting bronchodilators, inhaled steroids, and oral or intravenous steroids.
The distribution channels in the market are hospitals, diagnostic centres, and clinics, among others.
The different regions in the market are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is anticipated to hold a significant share of the market during the forecast period.
The bronchodilators help manage obstruction and inflammation of bronchial muscles caused due to the associated pulmonary disorders like emphysema, asthma, bronchitis, or chronic obstructive pulmonary disease (COPD).
The key companies involved in the market are Novartis International AG, GSK plc, Merck & Co., Inc., AstraZeneca plc, C. H. Boehringer Sohn Co. KG, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sunovion Pharmaceuticals Inc., Amphstar Pharmaceuticals, Inc., and Pfizer, Inc., among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share